Ashwagandha: What the evidence suggests for stress, sleep and exercise
A calm look at the evidence behind ashwagandha’s stress‑relief, sleep‑support and exercise claims, plus practical tips for trying it safely this week.
According to Patient.info FeatureArticle, ashwagandha (Withania somnifera) is an herb long used in Ayurvedic medicine and now marketed as a natural way to cope with stress, improve sleep and boost physical performance. The growing popularity matters because many people turn to supplements without a clear picture of how the plant works, what the research actually shows, and who should be cautious.
How ashwagandha is thought to work
Ashwagandha is labelled an adaptogen, a term used for substances that purportedly help the body maintain balance (homeostasis) when faced with physical or mental stress. The key proposed mechanisms are:
- Cortisol modulation – laboratory studies suggest compounds called withanolides can blunt the activity of the hypothalamic‑pituitary‑adrenal (HPA) axis, leading to lower circulating cortisol, the hormone released during stress.
- Antioxidant activity – withanolides also appear to scavenge free radicals and reduce oxidative stress, which can protect nerve cells and muscle tissue.
- Immune‑stimulating effects – the herb may up‑regulate certain cytokines, an effect that could be helpful in some contexts but potentially harmful for autoimmune conditions.
These mechanisms are biologically plausible, but most human data come from short‑term randomised controlled trials (RCTs) that used relatively high‑dose extracts lasting a few weeks to three months.
What the evidence actually shows
| Form | Typical dose | Evidence strength* | Notes |
|---|---|---|---|
| Capsules (standardised extract) | 300‑600 mg daily | Moderate (several RCTs) | Most research uses a 5 % withanolide extract; benefits on stress and sleep are modest but statistically significant. |
| Powder (root) | 1‑3 g daily | Low (small trials) | Potency varies; few studies assess pure powder. |
| Liquid extract | 2‑4 ml daily | Low (few trials) | Less standardised; dosage often based on manufacturer recommendation. |
| Tea (dried root) | 1‑2 tsp per cup | Very low (mostly anecdotal) | Traditional preparation; minimal clinical data. |
*Evidence strength reflects the number, size and quality of peer‑reviewed RCTs up to September 2026.
Stress and anxiety – Three moderate‑size RCTs (total ≈ 180 participants) reported reductions in self‑rated anxiety scores and salivary cortisol after 8‑12 weeks of 300‑600 mg daily extract. The effect size is comparable to that of low‑dose benzodiazepines in some trials, but confidence intervals are wide and participants were generally healthy adults.
Sleep quality – Two RCTs measured the Pittsburgh Sleep Quality Index (PSQI) and found improvements of 1‑2 points after 6‑8 weeks of supplementation. Objective sleep architecture (e.g., REM latency) was not consistently recorded, so we cannot claim a change in deep sleep stages.
Exercise performance – A meta‑analysis of five trials involving resistance‑trained adults (n ≈ 150) showed a modest increase in bench‑press strength (≈ 4 kg) and a 5‑% rise in muscle‑size markers after 8‑12 weeks of 500 mg daily extract. The gains appear to be driven by reduced perceived exertion rather than a direct anabolic effect.
Hormone levels – One small trial in men with low testosterone (n = 30) reported a rise in total testosterone of about 15 % after 12 weeks of 600 mg daily extract. No change in sperm count was observed, and the study lacked a placebo group, so the finding remains tentative.
Overall, the evidence suggests modest benefits for stress and sleep, with a slightly stronger signal for muscle strength in resistance training. Most benefits emerge after 2‑8 weeks of regular use.
How ashwagandha compares with other common stress‑support options
| Option | Typical dose | Main evidence base | Typical cost (UK) | Key advantage |
|---|---|---|---|---|
| Ashwagandha extract | 300‑600 mg | Moderate RCTs (stress, sleep) | £15‑£25 for 30 days | Plant‑based, may aid exercise |
| Magnesium glycinate | 200‑400 mg | Strong RCTs for insomnia & anxiety | £8‑£12 for 30 days | Well‑tolerated, cheap |
| Valerian root (tea/extract) | 300‑600 mg | Moderate RCTs for sleep latency | £10‑£18 for 30 days | Sedative effect for night‑time |
| Prescription SSRI (e.g., sertraline) | 50‑100 mg | Large RCTs for anxiety/depression | NHS‑covered | Clinically robust, regulated |
Ashwagandha sits between lifestyle nutrients (magnesium) and prescription medication. It offers a broader claim set (stress, sleep, exercise), but the evidence is less robust than that for magnesium on sleep or SSRIs on anxiety.
Who is likely to benefit, and who should be cautious
Potential beneficiaries
- Adults with mild‑to‑moderate stress who are looking for a non‑pharmacological option.
- Recreational exercisers or athletes seeking a small boost in perceived effort and recovery.
- People with occasional sleep difficulties who prefer a botanical over a sedative.
Groups that should avoid or seek professional advice
- Pregnant or trying to conceive – the herb can stimulate uterine activity and the safety profile is unclear.
- Breast‑feeding mothers – insufficient data, so avoidance is prudent.
- Individuals with autoimmune diseases (e.g., rheumatoid arthritis, lupus, multiple sclerosis) – immune‑stimulating effects could exacerbate symptoms.
- People on thyroid medication, antihypertensives, anxiolytics or sedatives – ashwagandha may interact by altering hormone levels or enhancing sedative effects.
- Those with known hypersensitivity to plants in the Solanaceae family – rare but reported rash cases.
The trade‑off here is that while short‑term use (up to three months) appears safe for most healthy adults, the long‑term safety is still unknown. The source notes that side effects such as diarrhoea or drowsiness may occur, and that anyone experiencing persistent symptoms should stop and consult a clinician.
What could go wrong or remains uncertain
The source flags several gaps:
- Long‑term safety – no studies extend beyond 12‑week periods, so cumulative effects on liver, kidney or endocrine function are speculative.
- Standardisation – commercial products vary in withanolide content; a 300 mg capsule might contain anywhere from 5‑10 % active compounds, influencing efficacy.
- Population bias – most trials recruited relatively young, healthy participants; results may not translate to older adults or people with chronic illness.
- Interaction data – pharmacokinetic studies (how the herb affects drug metabolism) are sparse, leaving uncertainty for people on multiple prescriptions.
- Placebo effect – many stress‑related outcomes rely on self‑report scales, which are vulnerable to expectancy bias.
In practice, this usually means a cautious, time‑limited trial is the safest way to gauge personal response.
A practical plan for the coming week
If you’re curious about trying ashwagandha, consider the following low‑risk protocol, keeping the NHS advice to check with a GP if you have any health conditions or take regular medication:
- Choose a reputable brand – look for a product that specifies a standardised 5 % withanolide extract and provides a batch‑specific certificate of analysis.
- Start with a modest dose – 300 mg taken in the evening for the first two weeks. This timing aligns with the herb’s calming reputation and may help you notice any impact on sleep.
- Track outcomes – use a simple diary to note daily stress rating (0‑10), time taken to fall asleep, and any side effects. After two weeks, increase to 600 mg if you tolerate it well and feel no benefit.
- Set a stop date – limit use to eight weeks unless you have consulted a healthcare professional. Discontinue if you develop gastrointestinal upset, dizziness, or any worsening of existing conditions.
- Combine with proven basics – maintain regular physical activity, balanced diet, and good sleep hygiene. Ashwagandha should complement, not replace, these foundations.
By the end of the week you’ll have a clear sense of whether the herb fits into your routine, without committing to an indefinite regimen.
